Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma

[1]  S. Steinberg,et al.  Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Maher,et al.  Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Bennett,et al.  Thalidomide-associated deep vein thrombosis and pulmonary embolism. , 2002, The American journal of medicine.

[4]  B. Rini,et al.  A high rate of venous thromboembolism in a multi‐institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma , 2002, Cancer.

[5]  P. Thall,et al.  A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma , 2002, Cancer.

[6]  B. Escudier,et al.  Phase II trial of thalidomide in renal-cell carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Hannes Kaufmann,et al.  Thromboembolic events during treatment with thalidomide. , 2002, Blood.

[8]  R. Motzer,et al.  Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Barlogie,et al.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.

[10]  S. Steinberg,et al.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  C. Boshoff,et al.  Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer , 2000, British Journal of Cancer.

[12]  R. Bukowski.  Natural history and therapy of metastatic renal cell carcinoma , 1997, Cancer.

[13]  T. Olencki,et al.  Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. , 1997, Journal of immunotherapy.

[14]  N. Mulder,et al.  Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Motzer,et al.  Phase II trial of thalidomide for patients with advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Robert W. Colman.  Hemostasis and thrombosis: Basic principles and clinical practice , 1987 .

[17]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.